(1) American Family Physician, The American Academy of Family Physicians, An
Algorithm for the Evaluation of Peripheral Neuropathy
, Feb 15, 1998 , CLICK HERE to
read the article.   

(2) Berkson BM.
A conservative triple antioxidant approach to the treatment of hepatitis
C. Combination of alpha lipoic acid (thioctic acid), silymarin, and selenium: three case
histories
. Med Klin. 1999;94 Suppl 3:84-89, CLICK HERE to read the article

(3) Konlee M. New treatments for hepatitis B and C [antigen-specific transfer for A, B &
C (chisolm biologicals) and thymate]
. Posit Health News. 1998 Fall;(No 17):19-21

(4) van der Goes A, Brouwer J, Hoekstra K, Roos D, van den Berg TK, Dijkstra CD.  
Reactive oxygen species are required for the phagocytosis of myelin by macrophages.  
J Neuroimmunol. 1998 Dec 1;92(1-2):67-75,
CLICK HERE to read the article.

(5) Morini M, Roccatagliata L, Dell'Eva R, Pedemonte E, Furlan R, Minghelli S, Giunti D,
Pfeffer U, Marchese M, Noonan D, Mancardi G, Albini A, Uccelli A. of the Molecular
Oncology Laboratory, National Cancer Research Institute, Genoa, Italy.  
Alpha-lipoic
acid is effective in prevention and treatment of experimental autoimmune
encephalomyelitis
.  J Neuroimmunol. 2004 Mar;148(1-2):146-53.  CLICK HERE to read
the article.

(6) Marracci GH, Jones RE, McKeon GP, Bourdette DN of the Department of Neurology,
Oregon Health and Science University, Portland, OR 97201, USA.
Alpha lipoic acid
inhibits T cell migration into the spinal cord and suppresses and treats experimental
autoimmune encephalomyelitis
. J Neuroimmunol. 2002 Oct;131(1-2):104-14. CLICK
HERE to read the article.

(7) Joseph Mercola, MD.  Non-Drug Approaches to Hepatitis C Ignored by "Awareness"
Campaign
, The Washington Post, October 31, 2000.  CLICK HERE to read this article.

(8) National Institute of Health, Study Phase, ClinicalTrials.gov

(9) S. C.J. Huijbregts, PhD, N. F. Kalkers, MD PhD, L. M.J. de Sonneville, PhD, V. de
Groot, MD PhD, I. E.W. Reuling, MSc and C. H. Polman, MD PhD.  
Differences in
cognitive impairment of relapsing remitting, secondary, and primary progressive MS
,
NEUROLOGY 2004;63:335-339, © 2004 American Academy of Neurology.  
CLICK HERE
to read this abstract

(10) MedMaster™, a product of the American Society of Health-System Pharmacists
(ASHP)

(11) USP DI® Advice for the Patient® , a product of the
United States Pharmacopeia
(USP).

(12) Bruce Ames, Senior Scientist at Children's Hospital Oakland Research Institute,
California,
Health for Life, Newsweek January 17, 2005, pp 52, 55.